Robin Norman, MD
Psychiatry · Washington Court House, OHNPI 1760421721
Payments from drug & device makers
Across 462 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$601
- Alkermes, Inc.$570
- plus $3K from 15 others
What the payments were for
- Food & beverage$8,093100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 48 | $1,168 |
| Teva Pharmaceuticals USA, Inc. | 85 | $1,150 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,048 |
| AbbVie(2 entities) | 59 | $1,004 |
| Neurocrine Biosciences, Inc. | 32 | $601 |
| Alkermes, Inc. | 34 | $570 |
| Lundbeck LLC | 23 | $417 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $409 |
| Supernus Pharmaceuticals, Inc. | 16 | $303 |
| Indivior Inc. | 14 | $259 |
| Ironshore Pharmaceuticals Inc. | 14 | $246 |
| Sunovion Pharmaceuticals Inc. | 13 | $243 |
| Axsome Therapeutics, Inc. | 6 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $173 |
| Johnson & Johnson | 6 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Shire North American Group Inc | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Adlon Therapeutics L.p. | 1 | $13 |
How this compares
$8,095 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 28 | $313,954 |
| IngrezzaValbenazine Tosylate | 22 | $185,047 |
| Invega SustennaPaliperidone Palmitate | 29 | $76,242 |
| Abilify MaintenaAripiprazole | 23 | $65,092 |
| FanaptIloperidone | 25 | $57,456 |
| CaplytaLumateperone Tosylate | 16 | $26,042 |
| Aripiprazole | 81 | $10,910 |
| Lurasidone Hcl | 23 | $9,666 |
| TrintellixVortioxetine Hydrobromide | 20 | $8,973 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,248 |
| LoxapineLoxapine Succinate | 17 | $2,434 |
| Clozapine | 33 | $2,411 |
| Oxcarbazepine | 35 | $1,657 |
| Divalproex Sodium | 96 | $1,625 |
| Fluphenazine Hcl | 11 | $1,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $1,150 | $316,38845 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $601 | $185,04722 claims |
| Johnson & JohnsonInvega Sustenna | $93 | $76,24229 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,048 | $65,09223 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,168 | $57,45625 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $409 | $26,04216 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $173 | $16,22039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Washington Court House
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.